Affimed NV
Company Profile
Business description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Contact
Gottlieb-Daimler-Strabe 2
MannheimBW68165
DEUT: +49 621560030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
78
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,148.90 | 93.60 | 1.16% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,968.59 | 3.96 | 0.01% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,700.75 | 50.04 | -0.28% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,054.72 | 8.79 | 0.07% |
| S&P 500 | 5,665.93 | 9.36 | -0.16% |
| S&P/ASX 200 | 7,918.90 | 90.60 | 1.16% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |